WO2012148181A3 - 약물 방출제어용 조성물 - Google Patents

약물 방출제어용 조성물 Download PDF

Info

Publication number
WO2012148181A3
WO2012148181A3 PCT/KR2012/003223 KR2012003223W WO2012148181A3 WO 2012148181 A3 WO2012148181 A3 WO 2012148181A3 KR 2012003223 W KR2012003223 W KR 2012003223W WO 2012148181 A3 WO2012148181 A3 WO 2012148181A3
Authority
WO
WIPO (PCT)
Prior art keywords
release
controlled
composition
present
drugs
Prior art date
Application number
PCT/KR2012/003223
Other languages
English (en)
French (fr)
Other versions
WO2012148181A2 (ko
Inventor
최연웅
조상민
민병구
박진하
김보경
Original Assignee
한국유나이티드제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국유나이티드제약 주식회사 filed Critical 한국유나이티드제약 주식회사
Publication of WO2012148181A2 publication Critical patent/WO2012148181A2/ko
Publication of WO2012148181A3 publication Critical patent/WO2012148181A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 약물 방출제어용 조성물에 관한 것이다. 구체적으로, 본 발명의 약물 방출제어용 조성물은 매트릭스 유형의 서방용 고분자가 기본 골격을 이루고, pH에 따라 졸-겔 변환이 일어나는 카보머로 상기 서방용 고분자의 방출제어능을 확충한다. 본 발명은 특히 방출 대상인 약물이 고난용성인 경우에 적합하도록 가용화제를, 그리고 충분한 초기 방출을 위해 붕해제를 추가로 함유함을 특징으로 한다. 본 발명의 약물 방출제어용 조성물은 서방용 고분자가 갖는 종래 매트릭스 구조의 서방성을 보유하면서, 졸-겔 변환성질을 가진 카보머를 도입하여 용출 후기 매트릭스 구조의 붕괴로 인한 약물의 급격한 방출을 예방할 수 있다. 아울러, 가용화제의 도입으로 인해 고난용성의 약물이 방출 이후에도 용해되지 않는 문제점을 해결하였으며, 붕해제를 도입하여 서방성 제제의 한계인 초기 방출속도를 향상시켰다.
PCT/KR2012/003223 2011-04-29 2012-04-26 약물 방출제어용 조성물 WO2012148181A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110041150A KR20130106456A (ko) 2011-04-29 2011-04-29 약물 방출제어용 조성물
KR10-2011-0041150 2011-04-29

Publications (2)

Publication Number Publication Date
WO2012148181A2 WO2012148181A2 (ko) 2012-11-01
WO2012148181A3 true WO2012148181A3 (ko) 2012-12-20

Family

ID=47072908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/003223 WO2012148181A2 (ko) 2011-04-29 2012-04-26 약물 방출제어용 조성물

Country Status (2)

Country Link
KR (1) KR20130106456A (ko)
WO (1) WO2012148181A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2907508A1 (en) * 2014-02-14 2015-08-19 Shin-Etsu Chemical Co., Ltd. Hydroxyalkylalkyl cellulose for tableting and solid preparation comprising the same
KR101748215B1 (ko) * 2015-05-29 2017-06-20 한국유나이티드제약 주식회사 경구용 서방성 제제
KR20180058644A (ko) * 2016-11-24 2018-06-01 에스케이케미칼 주식회사 바레니클린 서방성 제제 및 이의 제조 방법
CN114404379B (zh) * 2022-01-29 2024-01-26 杭州沐源生物医药科技有限公司 一种瑞巴派特缓释片及其制备方法
WO2024037982A1 (en) * 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144585B1 (en) * 1999-03-25 2006-12-05 Otsuka Pharmaceutical Co., Ltd. Cilostazol preparation
KR20070024254A (ko) * 2005-08-26 2007-03-02 한국오츠카제약 주식회사 실로스타졸 함유 서방정
KR20070118444A (ko) * 2006-06-12 2007-12-17 신풍제약주식회사 록소프로펜 또는 잘토프로펜 함유 제어방출성 제제 및 그의제조방법
KR20100027337A (ko) * 2008-09-02 2010-03-11 한국유나이티드제약 주식회사 용출률 향상과 부작용 발현이 최소화된 실로스타졸 서방정
US20110014282A1 (en) * 2008-02-28 2011-01-20 De Vasconcelos Teofilo Cardoso Pharmaceutical composition for poorly soluble drugs
KR20110132170A (ko) * 2010-06-01 2011-12-07 한국유나이티드제약 주식회사 1일 1회 투여로 최적의 약리학적 임상 효과를 제공하는 아세클로페낙 서방성 제제

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144585B1 (en) * 1999-03-25 2006-12-05 Otsuka Pharmaceutical Co., Ltd. Cilostazol preparation
KR20070024254A (ko) * 2005-08-26 2007-03-02 한국오츠카제약 주식회사 실로스타졸 함유 서방정
KR20070118444A (ko) * 2006-06-12 2007-12-17 신풍제약주식회사 록소프로펜 또는 잘토프로펜 함유 제어방출성 제제 및 그의제조방법
US20110014282A1 (en) * 2008-02-28 2011-01-20 De Vasconcelos Teofilo Cardoso Pharmaceutical composition for poorly soluble drugs
KR20100027337A (ko) * 2008-09-02 2010-03-11 한국유나이티드제약 주식회사 용출률 향상과 부작용 발현이 최소화된 실로스타졸 서방정
KR20110132170A (ko) * 2010-06-01 2011-12-07 한국유나이티드제약 주식회사 1일 1회 투여로 최적의 약리학적 임상 효과를 제공하는 아세클로페낙 서방성 제제

Also Published As

Publication number Publication date
WO2012148181A2 (ko) 2012-11-01
KR20130106456A (ko) 2013-09-30

Similar Documents

Publication Publication Date Title
WO2012148181A3 (ko) 약물 방출제어용 조성물
HRP20171518T1 (hr) Tabletni pripravak bez prouzrokovanja kvarova kod tabletiranja
JP2012530141A5 (ko)
WO2014165308A3 (en) Microsphere drug delivery system for sustained intraocular release
SG190448A1 (en) Rapidly dispersing granules, orally disintegrating tablets and methods
WO2006127044A3 (en) Pharmaceutical formulations useful for inhibiting acid secretion
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
CL2013003331A1 (es) Tableta de liberacion inmediata a prueba de alteracion que comprende (i) una matriz, y (ii) una pluralidad de material particulado, que comprende un opiaceo y un polimero de oxido de polietileno de mas de 20.000 g/mol, donde el multiparticulado forma una fase discontinua dentro de la matriz.
CO6670598A2 (es) Forma de dosificación resistente a alteración que comprende un polímero aniónico
WO2008084504A3 (en) Pharmaceutical compositions of angiotensin ii receptor blockers
MY173823A (en) Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
BR112015022985A2 (pt) Microesferas de buprenorfina de carga de fármaco alta e método para produção das mesmas
WO2011115969A3 (en) Process of manufacturing a lyophilized fast dissolving, muti-phasic dosage form
WO2008067037A3 (en) Novel formulations of proton pump inhibitors and methods of using these formulations
JP2011241218A5 (ko)
WO2011089595A3 (en) Sustained-release nucleic acid matrix compositions
WO2012002644A3 (en) Sustained-release pharmaceutical composition containing pramipexole or pharmaceutically acceptable salt thereof with improved stability
WO2011147026A3 (en) A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
WO2010082220A3 (en) Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
WO2012052834A3 (en) Multiple unit particulate system comprising metoprolol succinate
WO2009028598A1 (ja) 徐放性製剤及びその製造方法
WO2014041489A3 (en) Rapidly dissolving pharmaceutical composition
BRPI0418283A (pt) formulação de liberação prolongada e processo para a preparação de uma formulação de liberação prolongada
ES2625873T3 (es) Método de preparación de micropartículas biodegradables que contienen fármacos

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12777014

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013027844

Country of ref document: BR

122 Ep: pct application non-entry in european phase

Ref document number: 12777014

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112013027844

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20131029